Abstract: Objective To evaluate the efficacy of Kangfuxin Liquid in radioactive esophagitis caused by radiotherapy for malignant tumors. Methods Medline，PubMed，CNKI，WanFang Date and VIP databases were searched to find clinical controlled trials of Kangfuxin liquid for prevention and treatment of radiation esophagitis caused by radiotherapy for malignant tumors from inception to December 2018. According to the inclusion and exclusion criteria，screened the literature，extracted data and evaluated the quality. Meta-analysis was performed by RevMan 5.0 software. Results A total of 6 literatures were included，involving 482 patients of whom，237 cases of Kangfuxin liquid（experimental group） and 245 cases of conventional comprehensive western medicine therapy or routine health education（control group）. Meta-analysis showed that there were no significant differences in the incidence of grade Ⅰ，grade Ⅲand above lesions between the experimental group and the control group（RR=1.36，95%CI：0.96-1.95，P=0.09；RR=0.22，95%CI：0.04-1.25，P=0.09）. However，the incidence of grade Ⅱ injury in the experimental group was lower than that in the control group，and the difference was statistically significant（RR=0.53，95%CI： 0.37-0.77，P=0.0006）. The toxicity score of radioactive esophagitis in the experimental group was also significantly lower than that in the control group（MD=-0.31， 95%CI：-0.47--0.16，P<0.0001）. Conclusion In the course of radiotherapy for malignant tumors，the Kangfuxin liquid can effectively reduce the incidence of grade Ⅱ injury of radiation esophagitis，but there is no obvious advantage in reducing the damage of grade Ⅰ，grade Ⅲ and above lesions.

Key words: Kangfuxin liquid, Radiotherapy, Radioactive esophagitis, Meta-analysis